Vivus Resubmits Qnexa, But Limits Its Market Opportunity
This article was originally published in The Pink Sheet Daily
The biotech once again submits its application to FDA for its obesity drug, but the upside potential is drastically cut.
You may also be interested in...
Plus news on recent financing activity by Vivus, Aragon, 4s3 Bioscience and Amicus.
FDA appears to be testing weight loss agents against an easier-to-meet threshold for cardiovascular risk compared to diabetes drugs, based on Orexigen Therapeutics Inc.’s announcement of an agreement with the agency on a cardiovascular outcomes trial for its obesity agent Contrave (naltrexone/bupropion).
The biotech announces it will resubmit its obesity drug by the end of October, two months ahead of schedule, after a meeting with FDA.